NumFin

China Pioneer Pharma Holdings Limited

Sümbol: 1345.HK

HKSE

1.42

HKD

Turuhind täna

  • 13.7445

    P/E suhe

  • 0.0000

    PEG suhe

  • 1.67B

    MRK Cap

  • 0.04%

    DIV tootlus

China Pioneer Pharma Holdings Limited (1345-HK) Finantsaruanded

Download
AastaneQuarterly
LineaarneLog
Diagrammil näete China Pioneer Pharma Holdings Limited (1345.HK) vaikimisi numbreid dünaamikates. Companys revenue näitab keskmist NaN M, mis on NaN % gowth. Kogu perioodi keskmine brutokasum on NaN M, mis on NaN %. Keskmine brutokasumi suhtarv on NaN %. Ettevõtte eelmise aasta tulemuse puhaskasv on NaN %, mis on võrdne NaN % % keskmiselt kogu ettevõtte ajaloo jooksul.,

AastaneQuarterly
10Y20Y30Y40Y

Bilanss

Sukeldudes China Pioneer Pharma Holdings Limited fiskaalkäiguteele, täheldame keskmist varade kasvu. See määr on huvitaval kombel , mis kajastab nii ettevõtte kõrg- kui ka madalseisusid. Kui võrrelda kvartalite lõikes, siis kohandub see näitaja . Kui vaadata tagasi möödunud aastale, siis on varade kogumuutus NaN. Aktsionäride väärtus, mida näitab aktsionäride kogu omakapital, on hinnatud NaN aruandlusvaluutas. Selle aspekti aastane muutus on NaN%.

common:word.in-mln

USD
Growth
TTM202320222021202020192018201720162015201420132012

balance-sheet.row.cash-and-short-term-investments

0124.4289402.1
254.6
468.8
197.9
276.2
309.6
317.1
260.8
781.9
59.6

balance-sheet.row.short-term-investments

01075177.2
139.6
198.5
47
50
0
0
10
60
0

balance-sheet.row.net-receivables

0448.4413.2251.8
288
269.6
310.3
526.6
450.7
413.6
545
316.6
511.5

balance-sheet.row.inventory

0417.9321.1294.9
448.7
393.6
419.7
623.4
520.2
663.2
620
419.8
295.9

balance-sheet.row.other-current-assets

0126.2186.6241.5
275.4
300.6
202.4
103.7
128.5
143.5
585.4
343.5
0.1

balance-sheet.row.total-current-assets

01106.91134.91013.1
1127.1
1234.1
1083.2
1529.8
1409.1
1537.5
2011.2
1842
867

balance-sheet.row.property-plant-equipment-net

0247.4221.691.1
80.8
55.2
46.1
52.3
49.9
76.5
103.7
17.2
11.3

balance-sheet.row.goodwill

06.26.20
0
0
0
0
0
0
42.3
0
0

balance-sheet.row.intangible-assets

030.23745.9
47
12
14.1
15.2
15.9
61.2
158.4
15.2
18.2

balance-sheet.row.goodwill-and-intangible-assets

036.443.345.9
47
12
14.1
15.2
15.9
61.2
200.7
15.2
18.2

balance-sheet.row.long-term-investments

0117.1156.282.2
80.7
139.2
52.8
92.1
109.2
67.1
65.2
77
0

balance-sheet.row.tax-assets

02.38.612
19.5
7.8
8.6
5.4
5.9
2.1
2.3
2.1
6.3

balance-sheet.row.other-non-current-assets

020.7-8.6-12
-19.5
-7.8
-8.6
-5.4
-5.9
-2.1
-2.3
-2.1
25.7

balance-sheet.row.total-non-current-assets

0424421219.2
208.5
206.4
113
159.6
175
204.8
369.6
109.4
61.6

balance-sheet.row.other-assets

0015.896.1
92.8
110.1
241.6
144.6
164.4
79.8
174
45.5
0

balance-sheet.row.total-assets

01530.91571.71328.5
1428.4
1550.6
1437.8
1834
1748.5
1822
2554.9
1996.9
928.6

balance-sheet.row.account-payables

0284.9329.3262
360.7
263.5
143.3
568.9
419.7
426.1
391.8
329.2
244.4

balance-sheet.row.short-term-debt

061.329.614
15.1
49
101.1
34.3
79.4
287.9
611.1
429.5
416.2

balance-sheet.row.tax-payables

017.839.824.9
31.8
31.3
14.5
16.4
28.6
14.8
14.7
7.3
6

balance-sheet.row.long-term-debt-total

012.780.1
0
0.1
0
4.8
11.2
15.3
8.6
0.5
0

Deferred Revenue Non Current

041.443.643.6
19.4
-7.4
0
0
1.5
0.6
0
-7
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

00143.586.2
123.7
135.6
186.7
110.2
175
350.1
830.8
476.3
0.5

balance-sheet.row.total-non-current-liabilities

070.476.369.3
32.3
7.5
2
13.9
43.2
49.4
106.3
0.5
660.6

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
33.6
-660.6

balance-sheet.row.capital-lease-obligations

0148.70.2
0
0.2
4.6
10.1
14.4
17.3
9.3
26.1
0

balance-sheet.row.total-liab

0513.1549.2417.5
516.7
406.6
332
693
637.9
825.6
1328.9
839.6
715.7

balance-sheet.row.preferred-stock

0084.159
214.2
150.1
101.8
69.3
75.7
94.4
93.1
57.1
0

balance-sheet.row.common-stock

077.477.477.6
77.6
77.6
79.1
81.4
82.1
82.1
82.1
82.1
0

balance-sheet.row.retained-earnings

0634.9594.8444.2
590.5
538
433.4
361.5
297.9
202.9
181.3
175.6
88.5

balance-sheet.row.accumulated-other-comprehensive-income-loss

0929-84.1-59
-214.2
-150.1
-101.8
-69.3
-75.7
-94.4
-93.1
-57.1
-7.1

balance-sheet.row.other-total-stockholders-equity

0-634.9335.6386.2
241.4
526
592.1
766.5
806.6
807.5
957
957
130.7

balance-sheet.row.total-stockholders-equity

01006.41007.8908
909.4
1141.5
1104.6
1140.1
1110.9
998.1
1127.4
1157.6
212.1

balance-sheet.row.total-liabilities-and-stockholders-equity

01530.91571.71328.5
1428.4
1550.6
1437.8
1834
1748.5
1822
2554.9
1996.9
928.6

balance-sheet.row.minority-interest

011.314.73
2.3
2.4
1.3
0.9
-0.3
-1.6
98.6
-0.3
0.8

balance-sheet.row.total-equity

01017.81022.5911
911.7
1144
1105.9
1141.1
1110.6
996.4
1226
1157.3
212.8

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-

Total Investments

0117.1231.2259.4
220.3
337.8
99.8
142.1
109.2
67.1
65.2
137
14.2

balance-sheet.row.total-debt

07437.614.1
15.1
49
101.1
39.1
90.7
303.2
619.7
429.5
416.2

balance-sheet.row.net-debt

0-40.4-176.4-210.8
-99.9
-221.3
-49.7
-187
-219
-13.9
358.9
-272.5
356.7

Rahavoogude aruanne

China Pioneer Pharma Holdings Limited finantsmaastikul on viimase perioodi jooksul toimunud märkimisväärne muutus vabas rahavoos, mis näitab NaN nihet. Ettevõte laiendas hiljuti oma aktsiakapitali, emiteerides NaN, mis tähistab NaN erinevust võrreldes eelmise aastaga. Ettevõtte investeerimistegevuse tulemusel kasutas ettevõte netosularaha, mis aruandlusvaluutas oli NaN. See on NaN nihkumine võrreldes eelmise aastaga. Samal perioodil registreeris ettevõte NaN, NaN, NaN, mis on olulised ettevõtte investeerimis-ja tagasimaksestrateegiate mõistmiseks. Ettevõtte finantseerimistegevuse tulemusel kasutas ettevõte netorahavahendeid NaN, kusjuures erinevus võrreldes eelmise aastaga oli NaN. Lisaks eraldas ettevõte NaN aktsionäridele dividendide maksmiseks. Samal ajal tegi ta muid finantsmanöövreid, millele viidatakse kui NaN, mis samuti mõjutasid oluliselt tema rahavooge sel perioodil. Need komponendid koos annavad tervikliku pildi ettevõtte finantsseisundist ja strateegilisest lähenemisest rahavoogude juhtimisele.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010

cash-flows.row.net-income

0235.3142.652.4
104.6
84.6
278.9
237.4
174.3
261.7
238.4
206.8
123.1
96.9

cash-flows.row.depreciation-and-amortization

013.612.98.4
8.9
8.1
8.3
13.2
16.9
7.6
2.5
2.8
2.5
2

cash-flows.row.deferred-income-tax

0000
0
-385.2
194.6
-94.5
-35.1
0
0
0
0
0

cash-flows.row.stock-based-compensation

0000
0
0
-1.4
0.9
0.6
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-193.5226.3-147.3
4.8
385.3
-193.1
93.6
34.5
-296.2
-257.6
-47.7
-123.5
-1.2

cash-flows.row.account-receivables

0-16866.2-65.3
-20
180.5
-78.2
-6.7
111.6
-168.6
-130.8
0
0
0

cash-flows.row.inventory

0-25.5160.2-82.1
24.9
204.7
-114.9
100.3
-77.1
-127.6
-126.8
-56.3
-135.3
2.7

cash-flows.row.account-payables

0000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0000
0
0
0
0
0
0
0
8.6
11.8
-3.8

cash-flows.row.other-non-cash-items

037.9-139.8160.8
162.3
36
141
-3.1
78.4
9.1
64.7
-41.2
-23.9
-26.5

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-74.3-16.6-34.9
-8.9
-0.4
-9.7
-5.2
-6.1
-39.5
-16
-12.5
-4.7
-1.3

cash-flows.row.acquisitions-net

0-26.7-2.4-20.9
0.7
-7.8
-2
-62.1
-36.1
-110.6
-28.3
0
0
0

cash-flows.row.purchases-of-investments

0-717.2-2020.3-512.9
-697.9
-270.9
-50
0
-29.6
-78.1
-115.6
-15.7
0
0

cash-flows.row.sales-maturities-of-investments

0798.11976.4570.5
542.4
50
52
0
75.2
80
143.9
0
0
0

cash-flows.row.other-investing-activites

0771.422.1
81.1
30.4
49.7
61.2
417.5
-200.6
47.3
0.7
-142.6
47.3

cash-flows.row.net-cash-used-for-investing-activites

0-138.423.9
-82.6
-198.6
-12.1
-6.1
420.9
-348.7
-112.6
-27.5
-147.3
45.9

cash-flows.row.debt-repayment

0-1.10-0.1
-4.7
-61
-127.3
-483.5
-1103.2
-663.9
-484.8
-338
-142.9
-191.5

cash-flows.row.common-stock-issued

026.910.4-2.8
0
-1.9
-15.4
-0.9
-149.5
0
1097.9
0
0
0

cash-flows.row.common-stock-repurchased

0-25.8-10.3-2.8
-19.4
-74.9
-40.8
-0.9
-149.5
0
-383.5
0
0
0

cash-flows.row.dividends-paid

0-84.7-129.9-111.9
0
-137.8
-215.3
-142.5
-187.8
-256
-229.6
-147.6
-90
-36

cash-flows.row.other-financing-activites

0-6.4-10.4-135.5
-54.4
270.7
95.4
280.9
918.4
848.9
323
400.5
339.2
142.9

cash-flows.row.net-cash-used-provided-by-financing-activities

0-91-140.3-253
-78.5
-4.8
-303.3
-346.9
-671.6
-71
706.5
-85.1
106.3
-84.6

cash-flows.row.effect-of-forex-changes-on-cash

0-0.1-0.3-0.4
0
-0.5
-1.7
3.5
2.2
-3.8
0.7
0
-0.2
0

cash-flows.row.net-change-in-cash

0-10.8109.8-155.3
119.4
-75.3
-83.5
-7.5
56.3
-441.2
642.5
8.2
-63
32.5

cash-flows.row.cash-at-end-of-period

0214224.9115
270.3
150.9
226.2
309.6
317.1
260.8
702.1
59.6
51.4
114.3

cash-flows.row.cash-at-beginning-of-period

0224.9115270.3
150.9
226.2
309.6
317.1
260.8
702.1
59.6
51.4
114.3
81.9

cash-flows.row.operating-cash-flow

093.3242.174.2
280.6
128.7
233.6
342
304.7
-17.8
47.9
120.8
-21.8
71.2

cash-flows.row.capital-expenditure

0-74.3-16.6-34.9
-8.9
-0.4
-9.7
-5.2
-6.1
-39.5
-16
-12.5
-4.7
-1.3

cash-flows.row.free-cash-flow

019225.439.4
271.8
128.3
223.9
336.8
298.5
-57.3
31.9
108.3
-26.5
69.9

Kasumiaruande rida

China Pioneer Pharma Holdings Limited tulud muutusid võrreldes eelmise perioodiga NaN%. 1345.HK brutokasum on teatatud NaN. Ettevõtte tegevuskulud on NaN, mille muutus võrreldes eelmise aastaga on NaN%. Kulud amortisatsioonikulud on NaN, mis on NaN% muutus võrreldes eelmise aruandeperioodiga. Tegevuskulud on teatatud NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Müügi- ja turunduskulud on NaN, mis on NaN% muutus võrreldes eelmise aastaga. Hiljutistel numbritel põhinev EBITDA on NaN, mis tähendab NaN% kasvu võrreldes eelmise aastaga. Tegevustulu on NaN, mis näitab NaN% muutust võrreldes eelmise aastaga. Puhaskasumi muutus on NaN%. Eelmise aasta puhaskasum oli NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010

income-statement-row.row.total-revenue

01566.715561434.8
1332
1316
1624.3
2153.9
1790.3
1460.9
1540.4
1272.2
958.7
717.8
570.6

income-statement-row.row.cost-of-revenue

0898.4775.6662.8
724.1
636.2
991.9
1432.5
1196.9
998.3
1048.4
885.6
652
522.1
404.6

income-statement-row.row.gross-profit

0668.2780.5772
608
679.8
632.4
721.4
593.4
462.6
491.9
386.6
306.7
195.7
166.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

01.64.82.7
2.9
8.5
8.7
5.3
4
5.3
4.8
1.3
0.8
0.6
0.3

income-statement-row.row.operating-expenses

0488496.6574.6
519
543.3
541.6
428.4
324
276.8
210.3
113.5
109.4
79.1
71.1

income-statement-row.row.cost-and-expenses

01386.51272.11237.4
1243
1179.5
1533.5
1860.9
1520.8
1275.1
1258.7
999.1
761.4
601.2
475.6

income-statement-row.row.interest-income

00.610.64
6.3
12
16.3
16.3
12.9
21
23
0.7
14.4
7.5
5.8

income-statement-row.row.interest-expense

02.51.70.9
1.1
4
1.4
2.3
5.5
20
14.1
12.7
9.4
5.5
5

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

046.962.314.2
22.2
10
-42.5
24.7
39.8
-53.7
20.4
21.2
-7.8
-2.1
-5.3

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

01.64.82.7
2.9
8.5
8.7
5.3
4
5.3
4.8
1.3
0.8
0.6
0.3

income-statement-row.row.total-operating-expenses

046.962.314.2
22.2
10
-42.5
24.7
39.8
-53.7
20.4
21.2
-7.8
-2.1
-5.3

income-statement-row.row.interest-expense

02.51.70.9
1.1
4
1.4
2.3
5.5
20
14.1
12.7
9.4
5.5
5

income-statement-row.row.depreciation-and-amortization

018.913.212.7
8.1
8.7
8.1
8.3
13.2
16.9
7.6
2.5
2.8
2.5
2

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0133.5232.2187.2
73.1
138.5
149.7
284.6
242.6
260.5
284.3
251.3
214.6
125.1
102.1

income-statement-row.row.income-before-tax

0180.4294.5201.4
95.3
148.5
107.1
309.3
282.4
206.8
304.7
272.5
206.8
123.1
96.9

income-statement-row.row.income-tax-expense

051.564.560.6
43.9
44.6
22.3
28.7
43.7
34.3
43.7
36.7
21.1
26.1
21.8

income-statement-row.row.net-income

0145.7235.3142.6
52.4
104.6
84.6
278.9
237.4
174.3
261.7
238.4
186.4
95.7
70.4
Sarnased aktsiad
Sind võib huvitada ka:
MDVL
MedAvail Holdings, Inc..
1.8 USD
NASDAQ
3544.T
Satudora Holdings Co.,Ltd..
879 JPY
JPX
TSUSF
Tsuruha Holdings Inc..
86.95 USD
PNK
SHPPF
Shop Apotheke Europe N.V..
150.26 USD
PNK
3391.T
Tsuruha Holdings Inc..
11105 JPY
JPX
GABY.CN
GABY Inc..
0.005 CAD
CNQ
ALBHF
Alibaba Health Information Technology Limited.
0.4628 USD
PNK
WLCGF
Welcia Holdings Co., Ltd..
17.49 USD
PNK
OXIHF
Oxford Investments Holdings Inc..
0.000001 USD
PNK

Korduma kippuv küsimus

Mis on China Pioneer Pharma Holdings Limited (1345.HK) koguvara?

China Pioneer Pharma Holdings Limited (1345.HK) koguvara on 1530905000.000.

Mis on ettevõtte aastane tulu?

Aastane tulu on N/A.

Mis on ettevõtte kasumimarginaal?

Ettevõtte kasumimarginaal on 0.427.

Mis on ettevõtte vaba rahavoog?

Vaba rahavoog on -0.127.

Mis on ettevõtte puhaskasumimarginaal?

Puhaskasumimarginaal on 0.093.

Mis on ettevõtte kogutulu?

Kogutulu on 0.085.

Mis on China Pioneer Pharma Holdings Limited (1345.HK) puhaskasum (puhaskasum)?

Puhaskasum (netotulu) on 145718000.000.

Kui suur on ettevõtte koguvõlg?

Koguvõlg on 74020000.000.

Mis on tegevuskulude arv?

Tegevuskulud on 488030000.000.

Milline on ettevõtte rahaline näitaja?

Ettevõtte raha on 0.000.